Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized phase II trial of R-COP versus R-COPY in frail or vulnerable elderly patients with diffuse large B-cell lymphoma
2008-001506-16Phase 2Completed
- Sponsor
- Institut Bergonié
- Start
- Apr 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of rituximab, cyclophosphamide, vincristine, prednisone and doxorubicin in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Institut Bergonié. Primary endpoints: Complete remission at 6 months and Safety. Started Apr 2008; status: completed.
02
Drugs
rituximabcyclophosphamidevincristineprednisonedoxorubicin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2008-001506-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001506-16.